IL4 and asthma: These findings are in agreement with those of a previously published Cochrane intervention review assessing the efficacy and safety of anti-IL-13 or anti-IL-4 agents, in comparison with placebo, anti-IgE or anti-IL-5 agents, for the treatment of patients with asthma.